Results

1–2 of 2 results for tolerability

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021